Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

8.310 -0.110 (-1.31%)
Streaming Delayed Price Updated: 3:58 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ESAIY

< Previous 1 2 Next >
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug. 
Via Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
The FDA's advisors will consider the full approval of Leqembi on Friday. 
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market. 
Via Investor's Business Daily
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
The company is hopeful for maintenance dosing and a new injection of the drug. 
Via Investor's Business Daily
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
Biotech stocks are highly speculative, but it's possible to choose ones with excellent risk-reward ratios. 
Via InvestorPlace
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire. 
Via InvestorPlace
7 A-Rated Stocks to Buy for April 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape. 
Via InvestorPlace
7 Core Stocks to Build a Solid Portfolio Around
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation. 
Via InvestorPlace
7 Smart Stock Picks for Cautious Investors
As market volatility continues, consider playing it safe with these seven high-quality stocks for cautious investors. 
Via InvestorPlace
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.